UroGen Pharma enters $100M term loan facility with BPCR Limited Partnership

UroGen Pharma Ltd.

Term loans up to $100M; Tranche A $75M at closing, Tranche B $25M optional by Dec 31, 2022.
Interest rate 8.25% + 3-month LIBOR (floor 1.25%); quarterly interest; principal amortization starts after 17th quarter.
Secured by substantially all assets; no financial covenants; prepayment premiums (3%/2%/1%) and makewhole provisions.
Proceeds for general corporate and working capital; loan matures 5 years from Tranche A closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.